Veru Inc.
$582.2K 13 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Meridian Bioscience Inc.
Meridian Bioscience Inc. reported $576,968.94 across General Payments, Research, and Ownership to 246 physicians and teaching hospitals across 249 transactions.
- $577.0K Above-median payer
- All-tracks total
- 249 Above-median volume
- Transactions
- 246 Above-median reach
- Recipients
- +$68.4K
- General Payments vs PY2023
Meridian Bioscience Inc. reported $576,968.94 across all CMS Open Payments tracks (General + Research + Ownership) to 246 physicians and teaching hospitals in Program Year 2024 - ranking #730 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $173,680.80, averaging $2.3K per recipient.
How Meridian Bioscience Inc.'s $577.0K all-tracks total breaks down
Meridian Bioscience Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
19/100
Total payments
F
15/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer meridian-bioscience-inc Meridian Bioscience Inc.
$577.0K · #730/1,925 · 0.0% industry · PY2024
- TOT $577.0K
- RANK #730
- SHARE 0.0%
- TXN 249
- RCP 246
- CAT 3
- GEN $173.7K
- ΔGEN +$68.4K
- TOP1 29.1%
- PY 2024
Volume peers
Nearest volume peer: Veru Inc. ($582.2K)
Meridian Bioscience Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Meridian Bioscience Inc.'s CMS-reported General Payments increased by $68.4K (+64.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MERIDIAN BIOSCIENCE INC.PY2023: MERIDIAN BIOSCIENCE INC.PY2024: Meridian Bioscience Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $105,294.38
- PY2024
- $173,680.80
What the Data Shows for Meridian Bioscience Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Meridian Bioscience Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Compensation for Services Other Than Consulting" leads the 3-category general-payment breakdown below at $170.8K (98.3% of General Payments, 103 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Meridian Bioscience Inc.'s 3-category general-payment breakdown at $170.8K, 98.3% of the reported total.
How Meridian Bioscience Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $170.8K | 103 | 98.3% |
| Food and Beverage | $2.7K | 142 | 1.5% |
| Royalty or License | $225.00 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $162,853.20 (93.8%) of $173,680.80 in this company's General Payments records across 132 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Meridian Bioscience Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Northshore University Healthsystem
$50,524.00 across 24 reported transactions
- 2
Kaleida Health
$44,690.00 across 41 reported transactions
- 3
Tufts Medical Center
$29,700.00 across 2 reported transactions
- 4
Uhs Hospitals
$28,501.20 across 16 reported transactions
- 5
The University Of Texas Medical Br.
$9,438.00 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Meridian Bioscience Inc.'s spend rank (#730 of 1,925, top 38% by spend) and concentration rank (#731 of 1,838, top 40% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Embecta Corp. : $245.4K total payments, HHI 2146
- Allerderm Laboratories : $9.2K total payments, HHI 2140
- Route 92 Medical, Inc. : $704.7K total payments, HHI 2140
- Braintree Laboratories, Inc. : $652.0K total payments, HHI 2132
- elliquence, LLC : $336.3K total payments, HHI 2127
- Tosoh Bioscience, Inc. : $290.85 total payments, HHI 2118
- Meridian Bioscience Inc. (this company) : $173.7K total payments, HHI 2110
- Alaska Medical Technologies, Llc : $3.2K total payments, HHI 2108
- Ortho-Clinical Diagnostics, Inc. : $1.1M total payments, HHI 2099
- Endeavor Orthopaedics LLC : $427.85 total payments, HHI 2098
- MediView XR, Inc. : $31.1K total payments, HHI 2083
- Inquis Medical, Inc. : $58.0K total payments, HHI 2081
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Meridian Bioscience Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Meridian Bioscience Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Meridian Bioscience Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Zest Holdings, LLC
$571.1K 1,385 recipients
Compare payment profiles
Optos, Inc.
$585.3K 2,911 recipients
Compare payment profiles
Hyperfine Operations, Inc.
$568.6K 56 recipients
Compare payment profiles
Perfuze Limited
$568.2K 6 recipients
Compare payment profiles
Solta Medical, a division of Bausch Health US, LLC
$585.9K 1,270 recipients
Compare payment profiles
Put this to use
Meridian Bioscience Inc. ranks #730 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Meridian Bioscience Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.